JP2011506422A5 - - Google Patents

Download PDF

Info

Publication number
JP2011506422A5
JP2011506422A5 JP2010537542A JP2010537542A JP2011506422A5 JP 2011506422 A5 JP2011506422 A5 JP 2011506422A5 JP 2010537542 A JP2010537542 A JP 2010537542A JP 2010537542 A JP2010537542 A JP 2010537542A JP 2011506422 A5 JP2011506422 A5 JP 2011506422A5
Authority
JP
Japan
Prior art keywords
seq
antibody
variable region
chain variable
autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010537542A
Other languages
English (en)
Japanese (ja)
Other versions
JP5745274B2 (ja
JP2011506422A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2008/005011 external-priority patent/WO2010055366A2/en
Publication of JP2011506422A publication Critical patent/JP2011506422A/ja
Publication of JP2011506422A5 publication Critical patent/JP2011506422A5/ja
Application granted granted Critical
Publication of JP5745274B2 publication Critical patent/JP5745274B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2010537542A 2007-12-07 2008-12-08 抗ヒトｉｌ−２１モノクローナル抗体 Active JP5745274B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1232907P 2007-12-07 2007-12-07
US61/012,329 2007-12-07
PCT/IB2008/005011 WO2010055366A2 (en) 2007-12-07 2008-12-08 Anti-human il-21 monoclonal antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014036592A Division JP5848384B2 (ja) 2007-12-07 2014-02-27 抗ヒトｉｌ−２１モノクローナル抗体

Publications (3)

Publication Number Publication Date
JP2011506422A JP2011506422A (ja) 2011-03-03
JP2011506422A5 true JP2011506422A5 (enExample) 2011-12-01
JP5745274B2 JP5745274B2 (ja) 2015-07-08

Family

ID=40899470

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010537542A Active JP5745274B2 (ja) 2007-12-07 2008-12-08 抗ヒトｉｌ−２１モノクローナル抗体
JP2014036592A Active JP5848384B2 (ja) 2007-12-07 2014-02-27 抗ヒトｉｌ−２１モノクローナル抗体
JP2015230496A Active JP6027668B2 (ja) 2007-12-07 2015-11-26 抗ヒトｉｌ−２１モノクローナル抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014036592A Active JP5848384B2 (ja) 2007-12-07 2014-02-27 抗ヒトｉｌ−２１モノクローナル抗体
JP2015230496A Active JP6027668B2 (ja) 2007-12-07 2015-11-26 抗ヒトｉｌ−２１モノクローナル抗体

Country Status (18)

Country Link
US (5) US7883700B2 (enExample)
EP (3) EP3103813A1 (enExample)
JP (3) JP5745274B2 (enExample)
KR (2) KR101615215B1 (enExample)
CN (2) CN102027011B (enExample)
AU (1) AU2008364115B2 (enExample)
BR (1) BRPI0821168B8 (enExample)
CA (2) CA2707026C (enExample)
DK (1) DK2217268T3 (enExample)
ES (2) ES2584237T3 (enExample)
HU (1) HUE027828T2 (enExample)
IL (2) IL205976A (enExample)
MX (1) MX2010006181A (enExample)
PL (1) PL2217268T3 (enExample)
PT (1) PT2217268T (enExample)
RU (1) RU2504552C2 (enExample)
WO (1) WO2010055366A2 (enExample)
ZA (1) ZA201004046B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2805971A1 (en) 2005-11-28 2014-11-26 ZymoGenetics, Inc. IL-21 antagonists
EP3103813A1 (en) 2007-12-07 2016-12-14 ZymoGenetics, Inc. Anti-human il-21 monoclonal antibodies
WO2012012531A2 (en) * 2010-07-20 2012-01-26 Beth Israel Deaconess Medical Center, Inc. Compositions and methods featuring il-6 and il-21 antagonists
WO2012098113A1 (en) 2011-01-17 2012-07-26 Novo Nordisk A/S Il-21 ligands
US20140170153A1 (en) 2011-05-31 2014-06-19 Novo Nordisk A/S Il-21 epitope and il-21 ligands
SG11201401202YA (en) * 2011-10-19 2014-06-27 Morphosys Ag Antagonists of il17c for the treatment of inflammatory disorders
US20140178395A1 (en) * 2012-12-21 2014-06-26 Novo Nordisk A/S Treatment of nephropathy
US20140178396A1 (en) 2012-12-21 2014-06-26 Novo Nordisk A/S Treatment of cardiovascular diseases
EP3013858B1 (en) * 2013-06-27 2021-07-28 Monash University Il-21 binding proteins and uses thereof
CN103487572B (zh) * 2013-10-08 2017-03-29 北京大学人民医院 滤泡辅助性T淋巴细胞(Tfh)在自身免疫性疾病病情预警中的应用
CN104721820A (zh) * 2013-12-24 2015-06-24 信达生物制药(苏州)有限公司 双特异性单克隆抗体在治疗葡萄膜炎中的用途
WO2015132241A1 (en) * 2014-03-03 2015-09-11 Novo Nordisk A/S Treatment of inflammatory diseases
AR099625A1 (es) * 2014-03-21 2016-08-03 Lilly Co Eli Anticuerpos de il-21
SI3128997T1 (sl) * 2014-04-08 2020-11-30 Boston Pharmaceuticals Inc. Vezavne molekule specifične za IL-21 in njihove uporabe
ES2791879T3 (es) * 2014-05-07 2020-11-06 Novo Nordisk As Tratamiento de diabetes mediante el uso de GLP-1 y anti-IL-21
TWI668010B (zh) * 2014-05-07 2019-08-11 丹麥商諾佛 儂迪克股份有限公司 使用ｇｌｐ－１及抗ｉｌ－２１治療糖尿病
RU2609627C2 (ru) 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
EP3233120A4 (en) 2014-12-19 2018-05-30 Monash University Il-21 antibodies
EP3233914A1 (en) * 2014-12-19 2017-10-25 Mabtech Ab Composition, kit and method for inhibition of il-21 mediated activation of human cells
CA3018792C (en) * 2016-03-31 2023-03-28 Eli Lilly And Company Il-21 antibodies and uses thereof
WO2018045273A2 (en) * 2016-09-02 2018-03-08 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
JP6952295B2 (ja) * 2016-09-09 2021-10-20 国立大学法人金沢大学 ヒト抗ｈｌａモノクローナル抗体の作製方法
TWI901940B (zh) 2017-08-03 2025-10-21 美商安進公司 介白素-21突變蛋白及治療方法
JP2019122373A (ja) 2018-01-12 2019-07-25 アムジエン・インコーポレーテツド 抗ｐｄ−１抗体及び治療方法
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN116322740A (zh) * 2020-07-13 2023-06-23 特兰斯吉恩股份有限公司 免疫抑制的治疗
CN118370816A (zh) * 2024-03-22 2024-07-23 中日友好医院(中日友好临床医学研究所) Il-2/抗il-2抗体免疫复合物的应用
WO2025257327A1 (en) 2024-06-13 2025-12-18 Almirall, S.A. Therapeutic approaches for the management of hidradenitis suppurativa

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
DK1165791T3 (da) 1999-03-09 2008-02-11 Zymogenetics Inc Humant cytokin som zalpha-receptor-ligand og anvendelse deraf
DE60125543T2 (de) 2000-04-05 2007-10-04 Zymogenetics, Inc., Seattle Löslicher zytokinrezeptor zalpha11
ATE360696T1 (de) 2000-06-30 2007-05-15 Zymogenetics Inc Interferon-ähnliches protein zcyto21
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
EA010594B1 (ru) 2001-05-24 2008-10-30 Займодженетикс, Инк. Слитые белки taci-иммуноглобулина
MXPA04004167A (es) 2001-11-05 2004-07-08 Zymogenetics Inc Antagonistas de interleucina-21.
US20040028665A1 (en) 2002-01-08 2004-02-12 Garner Bryan E. Compositions and methods for inhibiting pathogenic growth
WO2003087320A2 (en) 2002-04-09 2003-10-23 Beth Israel Deaconess Medical Center, Inc. Antagonists of il-21 and modulation of il-21-mediated t cell responses
US20040016010A1 (en) 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
DK1531850T3 (da) 2002-06-07 2012-06-04 Zymogenetics Inc Anvendelse af 1L-21 og monoklonalt antistof til behandling af solide cancere
CN1688340A (zh) 2002-07-15 2005-10-26 韦思公司 调节t辅助(th)细胞发育和功能的方法和组合物
EP1572131B1 (en) 2002-10-08 2016-07-06 Immunomedics, Inc. Antibody therapy
US20070092485A1 (en) 2002-11-15 2007-04-26 Zymogenetics, Inc. Cytokine zalpha11 ligand
KR101098897B1 (ko) 2002-12-13 2011-12-26 지모제넥틱스, 인코포레이티드 원핵생물 숙주 내 ｉｌ-21 생산
CA2510787A1 (en) 2002-12-23 2004-07-08 Innate Pharma Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same
DE602004025332D1 (de) * 2003-03-14 2010-03-18 Wyeth Corp Antikörper gegen il21-rezeptor und deren verwendung
AU2004224277A1 (en) 2003-03-21 2004-10-07 Wyeth Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor
MXPA06004199A (es) 2003-10-17 2006-06-28 Novo Nordisk As Terapia en combinacion.
JP4471721B2 (ja) 2004-04-20 2010-06-02 独立行政法人産業技術総合研究所 抗インターロイキン２１受容体（ｉｌ−２１ｒ）抗体および本抗体を産生するハイブリドーマ
US20060024268A1 (en) 2004-05-19 2006-02-02 Wyeth Modulation of immunoglobulin production and atopic disorders
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
CA2574848A1 (en) 2004-08-05 2006-12-21 Wyeth Antagonizing interleukin-21 receptor activity
KR100654124B1 (ko) 2004-11-18 2006-12-08 주식회사 하이닉스반도체 벙커 디펙트를 억제할 수 있는 반도체 소자 제조 방법
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
WO2006105538A2 (en) * 2005-03-31 2006-10-05 Centocor, Inc. Methods and compositions for treating il-21 related pathologies
DK200501310A (da) * 2005-09-21 2005-10-01 Novo Nordisk As The invention relates to the treatment or prevention of autoimmune diseases and latent autoimmune diabetes in the adults
JP2009517406A (ja) 2005-11-28 2009-04-30 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２１受容体アンタゴニスト
EP2805971A1 (en) 2005-11-28 2014-11-26 ZymoGenetics, Inc. IL-21 antagonists
EP3103813A1 (en) 2007-12-07 2016-12-14 ZymoGenetics, Inc. Anti-human il-21 monoclonal antibodies

Similar Documents

Publication Publication Date Title
WO2010055366A4 (en) Anti-human il-21 monoclonal antibodies
JP7206303B2 (ja) 可変ドメインｖｌおよびｖｈｈ誘導体に基づく高アフィニティおよび凝集耐性抗体
JP2019162105A5 (enExample)
RU2474588C2 (ru) Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
DK2699601T3 (en) ANTIBODY POLYPEPTIDES ANTAGONIZING CD40
AU2011237679B2 (en) TNF-alpha binding proteins
CN111171150A (zh) 抗人tslp抗体及其用途
JP2010500005A5 (enExample)
US20080227704A1 (en) CXCL13 binding proteins
RU2011116927A (ru) Антитела против интерлейкина 17 (ил-17) человека и их применение
JP2011520898A5 (enExample)
CN101512008A (zh) 白介素-13结合蛋白
RU2011149334A (ru) Анти-il-17f антитела и способы их применения
JP2014513953A5 (enExample)
JP2015537190A5 (enExample)
JP6466904B2 (ja) インターフェロンアルファ及びオメガ抗体アンタゴニスト
CA3120102A1 (en) Engineered cd25 polypeptides and uses thereof
JP2013509158A5 (enExample)
CN114555642B (zh) 提升抗体对于抗原的亲和性的方法及其利用
JP7412440B2 (ja) アビド結合多重特異性抗体を作製する方法
JP2022060392A (ja) 抗体の抗原に対する親和性を制御する方法、抗原に対する親和性が改変された抗体及びその製造方法
CN116162160A (zh) 一种抗il-6的单域抗体及其用途
CN101679518B (zh) 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及用途
AU2015200579A1 (en) TNF-alpha binding proteins
CN111699006B (zh) Il17抗体及其应用